Journal of the American Society of Nephrology
2007 JASN IMPACT FACTOR 7.111 HOME   AUTHOR INFO   EDITORIAL BOARD   SUBSCRIBE   FEEDBACK   ALERTS   HELP 
    advanced
CURRENT ISSUE ARCHIVES JASN Express ONLINE SUBMISSION


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Goodman, W. G.
Right arrow Articles by Coburn, J. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Goodman, W. G.
Right arrow Articles by Coburn, J. W.
J Am Soc Nephrol 13:1017-1024, 2002
© 2002 American Society of Nephrology

The Calcimimetic Agent AMG 073 Lowers Plasma Parathyroid Hormone Levels in Hemodialysis Patients with Secondary Hyperparathyroidism

William G. Goodman*, Gerald A. Hladik{dagger}, Stewart A. Turner{ddagger}, Peter W. Blaisdell{ddagger}, David A. Goodkin{ddagger}, Wei Liu{ddagger}, Yousri M. Barri§, Raphael M. Cohen|| and Jack W. Coburn

*Department of Medicine, UCLA School of Medicine, Los Angeles, California; {dagger}Division of Nephrology, University of North Carolina, Chapel Hill, North Carolina; {ddagger}Amgen Inc., Thousand Oaks, California; §VA Medical Center, Little Rock, Arkansas; ||Presbyterian Medical Center, Philadelphia, Pennsylvania;and VA Medical Center, West Los Angeles, California.

Correspondence to: Dr. William G. Goodman, Division of Nephrology, 7-155 Factor Building, UCLA Medical Center, 10833 Le Conte Avenue, Los Angeles, CA 90095. Phone: 310-206-2650; Fax: 310-825-6309; E-mail: wgoodman{at}ucla.edu

ABSTRACT. Treatment with vitamin D sterols can lower plasma parathyroid hormone (PTH) in many patients with secondary hyperparathyroidism due to end-stage renal disease, but hypercalcemia, hyperphosphatemia, or both often develop during treatment. As such, alternative therapeutic approaches to managing excess PTH secretion are needed. Calcimimetic agents directly inhibit PTH secretion by activating the calcium-sensing receptor in the parathyroid glands, but clinical experience with them is limited. Fifty-two hemodialysis patients with secondary hyperparathyroidism were given single orally administered doses of the calcimimetic agent AMG 073 ranging from 5 to 100 mg, or placebo. Plasma PTH levels decreased 2 h after 25-, 50-, 75-, or 100-mg doses, falling by a maximum of 43 ± 29%, 40 ± 36%, 54 ± 28%, or 55 ± 39%, respectively. Plasma PTH levels decreased in all patients given doses of >=25 mg but did not change in those who received placebo. In patients treated with daily doses of 25 or 50 mg of AMG 073 for 8 d, plasma PTH levels declined for the first 3 to 4 d and remained below baseline values after 8 d of treatment. Serum calcium concentrations also decreased by 5 to 10% from pretreatment levels in patients given 50 mg of AMG 073 for 8 d, but values were unchanged in those who received lower doses. Serum phosphorus levels and values for the calcium-phosphorus ion product both decreased after treatment with AMG 073. Thus, 8 d of treatment with AMG 073 effectively lowers plasma PTH levels and improves several disturbances in mineral metabolism that have been associated with soft tissue and vascular calcification and with adverse cardiovascular outcomes in patients with end-stage renal disease.




This article has been cited by other articles:


Home page
 Nephrol Dial TransplantHome page
N. Giotta and A. Marino
Calcimimetics, calcium set point and calcium balance
Nephrol. Dial. Transplant., December 1, 2008; 23(12): 4083 - 4084.
[Full Text] [PDF]

Home page
 J. Am. Soc. Nephrol.Home page
C. Valle, M. Rodriguez, R. Santamaria, Y. Almaden, M. E. Rodriguez, S. Canadillas, A. Martin-Malo, and P. Aljama
Cinacalcet Reduces the Set Point of the PTH-Calcium Curve
J. Am. Soc. Nephrol., December 1, 2008; 19(12): 2430 - 2436.
[Abstract] [Full Text] [PDF]

Home page
 Nephrol Dial TransplantHome page
N. Kamar, I. Gennero, L. Spataru, L. Esposito, J. Guitard, L. Lavayssiere, O. Cointault, P. Gandia, D. Durand, and L. Rostaing
Pharmacodynamic effects of cinacalcet after kidney transplantation: once- versus twice-daily dose
Nephrol. Dial. Transplant., November 1, 2008; 23(11): 3720 - 3726.
[Abstract] [Full Text] [PDF]

Home page
 Nephrol Dial TransplantHome page
A. L. M. de Francisco, M. Izquierdo, J. Cunningham, C. Pinera, R. Palomar, G. F. Fresnedo, J. A. Amado, M. G. Unzueta, and M. Arias
Calcium-mediated parathyroid hormone release changes in patients treated with the calcimimetic agent cinacalcet
Nephrol. Dial. Transplant., September 1, 2008; 23(9): 2895 - 2901.
[Abstract] [Full Text] [PDF]

Home page
 Journal of Pharmacy PracticeHome page
P. P. How, D. L. Mason, and A. H. Lau
Current Approaches in the Treatment of Chronic Kidney Disease Mineral and Bone Disorder
Journal of Pharmacy Practice, June 1, 2008; 21(3): 196 - 213.
[Abstract] [PDF]

Home page
 NDT PlusHome page
C. Wiebe, J. Ho, B. Cohen, and C. Bohm
Spinal cord compression from a brown tumour despite maximal medical therapy with cinacalcet and sevelamer
NDT Plus, June 1, 2008; 1(3): 151 - 153.
[Full Text] [PDF]

Home page
 NDT PlusHome page
V. M. Brandenburg and J. Floege
Adynamic bone disease--bone and beyond
NDT Plus, June 1, 2008; 1(3): 135 - 147.
[Full Text] [PDF]

Home page
 Nephrol Dial TransplantHome page
U. Kunzendorf, B. K. Kramer, W. Arns, J. Braun, J. Grossmann, F. Pietruck, H. Schmidt-Gayk, A. Schwarz, E. Ziegler, H. Sperschneider, et al.
Bone disease after renal transplantation
Nephrol. Dial. Transplant., February 1, 2008; 23(2): 450 - 458.
[Full Text] [PDF]

Home page
 CJASNHome page
P. Messa, F. Macario, M. Yaqoob, K. Bouman, J. Braun, B. von Albertini, H. Brink, F. Maduell, H. Graf, J. M. Frazao, et al.
The OPTIMA Study: Assessing a New Cinacalcet (Sensipar/Mimpara) Treatment Algorithm for Secondary Hyperparathyroidism
Clin. J. Am. Soc. Nephrol., January 1, 2008; 3(1): 36 - 45.
[Abstract] [Full Text] [PDF]

Home page
 CJASNHome page
C. P. Kovesdy, R. Mehrotra, and K. Kalantar-Zadeh
Battleground: Chronic Kidney Disorders Mineral and Bone Disease Calcium Obsession, Vitamin D, and Binder Confusion
Clin. J. Am. Soc. Nephrol., January 1, 2008; 3(1): 168 - 173.
[Abstract] [Full Text] [PDF]

Home page
 NDT PlusHome page
A. L. M. de Francisco and F. Carrera
A New Paradigm for the Treatment of Secondary Hyperparathyroidism
NDT Plus, January 1, 2008; 1(suppl_1): i24 - i28.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
R. M. Fryer, J. A. Segreti, D. L. Widomski, P. H. Franklin, P. N. Banfor, K. A. Koch, M. Nakane, J. R. Wu-Wong, B. F. Cox, and G. A. Reinhart
Systemic Activation of the Calcium Sensing Receptor Produces Acute Effects on Vascular Tone and Circulatory Function in Uremic and Normal Rats: Focus on Central versus Peripheral Control of Vascular Tone and Blood Pressure by Cinacalcet
J. Pharmacol. Exp. Ther., October 1, 2007; 323(1): 217 - 226.
[Abstract] [Full Text] [PDF]

Home page
 Nephrol Dial TransplantHome page
A. L. Serra, R. Savoca, A. R. Huber, U. Hepp, A. Delsignore, M. Hersberger, and R. P. Wuthrich
Effective control of persistent hyperparathyroidism with cinacalcet in renal allograft recipients
Nephrol. Dial. Transplant., February 1, 2007; 22(2): 577 - 583.
[Abstract] [Full Text] [PDF]

Home page
 J. Am. Soc. Nephrol.Home page
A. L.M. de Francisco, C. Pinera, R. Palomar, and M. Arias
Impact of Treatment with Calcimimetics on Hyperparathyroidism and Vascular Mineralization
J. Am. Soc. Nephrol., December 1, 2006; 17(12_suppl_3): S281 - S285.
[Abstract] [Full Text] [PDF]

Home page
 Circ. Res.Home page
R. C. Johnson, J. A. Leopold, and J. Loscalzo
Vascular Calcification: Pathobiological Mechanisms and Clinical Implications
Circ. Res., November 10, 2006; 99(10): 1044 - 1059.
[Abstract] [Full Text] [PDF]

Home page
 CJASNHome page
T. R. Srinivas, J. D. Schold, K. L. Womer, B. Kaplan, R. J. Howard, C. M. Bucci, and H.-U. Meier-Kriesche
Improvement in Hypercalcemia with Cinacalcet after Kidney Transplantation
Clin. J. Am. Soc. Nephrol., March 1, 2006; 1(2): 323 - 326.
[Abstract] [Full Text] [PDF]

Home page
 J. Am. Soc. Nephrol.Home page
T. Odenwald, K. Nakagawa, C. Hadtstein, F. Roesch, P. Gohlke, E. Ritz, F. Schaefer, and C. P. Schmitt
Acute Blood Pressure Effects and Chronic Hypotensive Action of Calcimimetics in Uremic Rats
J. Am. Soc. Nephrol., March 1, 2006; 17(3): 655 - 662.
[Abstract] [Full Text] [PDF]

Home page
 J. Am. Soc. Nephrol.Home page
J. A. Coladonato
Control of Hyperphosphatemia among Patients with ESRD
J. Am. Soc. Nephrol., November 1, 2005; 16(11_suppl_2): S107 - S114.
[Abstract] [Full Text] [PDF]

Home page
 Eur J EndocrinolHome page
T. Kawata, Y. Imanishi, K. Kobayashi, T. Kenko, M. Wada, E. Ishimura, T. Miki, N. Nagano, M. Inaba, A. Arnold, et al.
Relationship between parathyroid calcium-sensing receptor expression and potency of the calcimimetic, cinacalcet, in suppressing parathyroid hormone secretion in an in vivo murine model of primary hyperparathyroidism
Eur. J. Endocrinol., October 1, 2005; 153(4): 587 - 594.
[Abstract] [Full Text] [PDF]

Home page
 Nephrol Dial TransplantHome page
S. M. Moe, J. Cunningham, J. Bommer, S. Adler, S. J. Rosansky, P. Urena-Torres, M. B. Albizem, M. D. Guo, V. J. Zani, W. G. Goodman, et al.
Long-term treatment of secondary hyperparathyroidism with the calcimimetic cinacalcet HCl
Nephrol. Dial. Transplant., October 1, 2005; 20(10): 2186 - 2193.
[Abstract] [Full Text] [PDF]

Home page
 Nephrol Dial TransplantHome page
A. E. Kruse, U. Eisenberger, F. J. Frey, and M. G. Mohaupt
The calcimimetic cinacalcet normalizes serum calcium in renal transplant patients with persistent hyperparathyroidism
Nephrol. Dial. Transplant., July 1, 2005; 20(7): 1311 - 1314.
[Abstract] [Full Text] [PDF]

Home page
 J. Am. Soc. Nephrol.Home page
J. S. Lindberg, B. Culleton, G. Wong, M. F. Borah, R. V. Clark, W. B. Shapiro, S. D. Roger, F. E. Husserl, P. S. Klassen, M. D. Guo, et al.
Cinacalcet HCl, an Oral Calcimimetic Agent for the Treatment of Secondary Hyperparathyroidism in Hemodialysis and Peritoneal Dialysis: A Randomized, Double-Blind, Multicenter Study
J. Am. Soc. Nephrol., March 1, 2005; 16(3): 800 - 807.
[Abstract] [Full Text] [PDF]

Home page
 Endocr. Rev.Home page
T. M. Murray, L. G. Rao, P. Divieti, and F. R. Bringhurst
Parathyroid Hormone Secretion and Action: Evidence for Discrete Receptors for the Carboxyl-Terminal Region and Related Biological Actions of Carboxyl- Terminal Ligands
Endocr. Rev., February 1, 2005; 26(1): 78 - 113.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
G. N. Kumar, C. Sproul, L. Poppe, S. Turner, M. Gohdes, H. Ghoborah, D. Padhi, and L. Roskos
METABOLISM AND DISPOSITION OF CALCIMIMETIC AGENT CINACALCET HCL IN HUMANS AND ANIMAL MODELS
Drug Metab. Dispos., December 1, 2004; 32(12): 1491 - 1500.
[Abstract] [Full Text] [PDF]

Home page
 The Annals of PharmacotherapyHome page
M. S Joy, A. V Kshirsagar, and N. Franceschini
Calcimimetics and the Treatment of Primary and Secondary Hyperparathyroidism
Ann. Pharmacother., November 1, 2004; 38(11): 1871 - 1880.
[Abstract] [Full Text] [PDF]

Home page
 J. Am. Soc. Nephrol.Home page
M. Mizobuchi, I. Hatamura, H. Ogata, F. Saji, S. Uda, K. Shiizaki, T. Sakaguchi, S. Negi, E. Kinugasa, S. Koshikawa, et al.
Calcimimetic Compound Upregulates Decreased Calcium-Sensing Receptor Expression Level in Parathyroid Glands of Rats with Chronic Renal Insufficiency
J. Am. Soc. Nephrol., October 1, 2004; 15(10): 2579 - 2587.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
A. K. Owda, M. G. Alam, J. Kumar, P. A. Urena Torres, J. Chanard, G. A. Block, and W. G. Goodman
Cinacalcet for Secondary Hyperparathyroidism in Hemodialysis Recipients
N. Engl. J. Med., July 8, 2004; 351(2): 188 - 189.
[Full Text] [PDF]

Home page
 Am. J. Physiol. Renal Physiol.Home page
R. A. Chen and W. G. Goodman
Role of the calcium-sensing receptor in parathyroid gland physiology
Am J Physiol Renal Physiol, June 1, 2004; 286(6): F1005 - F1011.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
G. A. Block, K. J. Martin, A. L.M. de Francisco, S. A. Turner, M. M. Avram, M. G. Suranyi, G. Hercz, J. Cunningham, A. K. Abu-Alfa, P. Messa, et al.
Cinacalcet for Secondary Hyperparathyroidism in Patients Receiving Hemodialysis
N. Engl. J. Med., April 8, 2004; 350(15): 1516 - 1525.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
G. Curhan
Fooling the Parathyroid Gland -- Will There Be Health Benefits?
N. Engl. J. Med., April 8, 2004; 350(15): 1565 - 1567.
[Full Text] [PDF]

Home page
 J. Am. Soc. Nephrol.Home page
H. Ogata, E. Ritz, G. Odoni, K. Amann, and S. R. Orth
Beneficial Effects of Calcimimetics on Progression of Renal Failure and Cardiovascular Risk Factors
J. Am. Soc. Nephrol., April 1, 2003; 14(4): 959 - 967.
[Abstract] [Full Text] [PDF]

Home page
 Nephrol Dial TransplantHome page
W. G. Goodman
Medical management of secondary hyperparathyroidism in chronic renal failure
Nephrol. Dial. Transplant., March 1, 2003; 18(90003): iii2 - 8.
[Abstract] [Full Text] [PDF]

Home page
 Nephrol Dial TransplantHome page
M. Wada and N. Nagano
Control of parathyroid cell growth by calcimimetics
Nephrol. Dial. Transplant., March 1, 2003; 18(90003): iii13 - 17.
[Abstract] [Full Text] [PDF]

Home page
 Nephrol Dial TransplantHome page
M. Fukagawa and S. Nakanishi
Role of parathyroid intervention in the management of secondary hyperparathyroidism
Nephrol. Dial. Transplant., March 1, 2003; 18(90003): iii23 - 26.
[Abstract] [Full Text] [PDF]

Home page
 Nephrol Dial TransplantHome page
K. Shiizaki, S. Negi, M. Mizobuchi, I. Hatamura, N. Narukawa, T. Sakaguchi, Y. Kitabata, S. Sumikado, and T. Akizawa
Effect of percutaneous calcitriol injection therapy on secondary hyperparathyroidism in uraemic patients
Nephrol. Dial. Transplant., March 1, 2003; 18(90003): iii42 - 46.
[Abstract] [Full Text] [PDF]

Home page
 J. Am. Soc. Nephrol.Home page
D. J. Sherrard
Manipulating the Calcium Receptor
J. Am. Soc. Nephrol., April 1, 2002; 13(4): 1124 - 1125.
[Full Text] [PDF]


HOME CURRENT ISSUE ARCHIVES JASN Express ONLINE SUBMISSION AUTHOR INFO
EDITORIAL BOARD SUBSCRIBE FEEDBACK ALERTS HELP

Copyright © 2008 by the American Society of Nephrology. Online ISSN: 1533-3450 Print ISSN: 1046-6673